Skip to main content

Day: May 1, 2024

Follow-Up Drilling to Commence at Nunyerry North and New Targets Defined Near Karratha

HIGHLIGHTS Nunyerry NorthAt Nunyerry North, a ~4,000 m RC drill program is to commence next week following significant results from the maiden drill program. The program will test multiple new targets along strike of known mineralisation and down plunge of existing intercepts. Significant intercepts from the maiden RC program at Nunyerry North1 included:6 m @ 6.12 g/t Au from 37 m (NC017) 11 m @ 2.52 g/t Au from 22 m, including 6 m at 4.19 g/t Au from 22 m (NC014) 13 m @ 1.89 g/t Au from surface (NC004) 4 m @ 5.71 g/t Au from 40 m (NC015) 17 m @ 1.34 g/t Au from 37 m, including 4 m at 3.77 g/t Au from 50 m (NC022) 14 m at 1.14 g/t Au from 39 m, including 4 m at 2.16 g/t Au from 41 m (NC006)The upcoming Nunyerry North drilling program successfully qualified for the Western Australian State Government Exploration Incentive Scheme...

Continue reading

Victory Square Technologies Reports 2023 Financial Results

A diverse portfolio of 25+ innovative companies from around the world (founders from: Ireland, Sri Lanka, Bulgaria, Australia, India, Brazil, the Middle East and North America) Sectors include: Digital Health, Artificial Intelligence (AI), Machine Learning (ML), Blockchain/Web3, Virtual & Augmented Reality (VR/AR), Gaming, Climate Tech Revenue for the year ended December 31, 2023, was $12,055,070 compared to $5,929,096 for the corresponding prior year period Cash & liquid securities approx. $4,903,363VANCOUVER, British Columbia, May 01, 2024 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (“Victory Square” or the “Company”) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company that gives investor access to a portfolio of 25+ innovative companies from around the world in a single stock, announces it has filed its Audited Annual...

Continue reading

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease Akari Therapeutics announces leadership changes in separate Akari press releaseBOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX, “Akari”) and Peak Bio Inc. (OTC: PKBO, “Peak”) today announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously announced merger of Akari and Peak, will focus on Peak’s ADC (antibody drug conjugate) platform technology and Akari’s PAS-nomacopan Geographic Atrophy (GA) program. Peak’s ADC platform technology is a proprietary technology using antibody plus linker plus Peak Bio toxin with immune modulation and includes a novel...

Continue reading

Locafy Reports Fiscal Third Quarter 2024 Results

Company Striving Towards Near-Term Profitability Following Go-to-Market Approach Revamp and Cost Reduction Initiatives New Pay-Per-Click SEO Pricing Model Gaining Strong Traction in Multiple Market Sectors Streamlined Operations Results in Record Quarterly Gross Margin of 83.6% PERTH, Australia, May 01, 2024 (GLOBE NEWSWIRE) — Locafy Limited (Nasdaq: LCFY, LCFYW) (“Locafy” or the “Company”), a globally recognized software-as-a-service technology company specializing in “entity-based” search engine optimization (SEO), today reported financial results for the 2024 fiscal third quarter ended March 31, 2024. All financial results are reported in Australian Dollars (AUD). Recent Operational HighlightsAnnounced in early April, Locafy’s new proprietary Performance-Based SEO Pricing Model allows customers to access “pay-per-click SEO.”...

Continue reading

Conduent Reports First Quarter 2024 Financial Results

Key Q1 2024 HighlightsRevenue: $921M Pre-tax Income: $127M Adj. EBITDA Margin(1): 7.5% New business signings ACV(2): $99M Net ARR Activity Metric(2) (TTM): $17MFLORHAM PARK, N.J., May 01, 2024 (GLOBE NEWSWIRE) — Conduent (NASDAQ: CNDT), a global technology-led business process solutions and services company, today announced its first quarter 2024 financial results. Cliff Skelton, Conduent President and Chief Executive Officer stated, “Q1 2024 is a continued reflection of progress in our portfolio performance overlaid by timing considerations and variations across our segments. While Revenue exceeded expectations and Adjusted EBITDA/Margin were broadly in line with expectations, sales performance lagged due to the timing of several opportunities between Q1 and Q2. The diversity of our portfolio is further evidenced by a strong...

Continue reading

Carpenter Technology Reports Third Quarter Fiscal Year 2024 Results

Exceeded Third Quarter Operating Income GuidanceIncreasing Fourth Quarter Operating Income OutlookGenerated Positive Free Cash Flow PHILADELPHIA, May 01, 2024 (GLOBE NEWSWIRE) — Carpenter Technology Corporation (NYSE: CRS) (the “Company”) today announced financial results for the fiscal third quarter ended March 31, 2024. For the quarter, the Company reported operating income of $75.9 million, and earnings per diluted share of $0.12. Excluding noncash special items discussed below, adjusted operating income was $90.0 million and adjusted earnings per diluted share was $1.19 for the current quarter. Third Quarter Fiscal Year 2024 HighlightsDelivered $90.0 million of adjusted operating income, up 29 percent sequentially and a record quarterly result Realized adjusted earnings per diluted share of $1.19 Increased net sales excluding...

Continue reading

CTS Announces First Quarter 2024 Results

Driving Operational Performance and Profitability; Continued Focus on Diversification LISLE, Ill., May 01, 2024 (GLOBE NEWSWIRE) — CTS Corporation (NYSE: CTS), a leading global designer and manufacturer of custom engineered solutions that “Sense, Connect and Move,” today announced first quarter 2024 results. “We achieved sales and earnings in line with our expectations. Our teams made progress on operational improvements in the first quarter, which helped offset the unfavorable impact from lower volumes. As anticipated, we are seeing some early signs of recovery in the industrial end market,” said Kieran O’Sullivan, CEO of CTS Corporation. “CTS is focused on future growth through continued diversification of our customer base and building our pipeline of opportunities. We remain committed to a disciplined capital structure to support...

Continue reading

SIPP Industries Announces Strategic Acquisition of Revenue Share in Calypso Pharmaceuticals to Bolster Position in Cannabis and Hemp Industries

COSTA MESA, Calif., May 01, 2024 (GLOBE NEWSWIRE) — Sipp Industries, Inc. (OTC: SIPC), a leading player in the cannabis and hemp industries, announces its strategic acquisition of revenue share in Calypso Pharmaceuticals, a Texas-based company renowned for its innovative products and proprietary technology in the cannabis and hemp sectors. The acquisition marks a significant milestone in SIPP Industries’ mission to expand its product portfolio and market presence. Calypso Pharmaceuticals specializes in developing niche products such as beverages, nasal sprays, edibles, topicals, and water-soluble nano-emulsified products tailored for the cannabis and hemp markets. With a focus on enhancing bioavailability, Calypso’s proprietary technology achieves an impressive 95% bioavailability, surpassing conventional isolate or...

Continue reading

Freddie Mac Announces First Quarter 2024 Financial Results

MCLEAN, Va., May 01, 2024 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today reported its First Quarter 2024 financial results and filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission. The company’s Form 10-Q and earnings press release, along with the First Quarter 2024 financial results supplement are available now on the Investor Relations page of the company’s website. The company will hold a call at 9 a.m. Eastern Time (ET) today, May 1, 2024, to share its results with the media. The call will be concurrently webcast, and the replay will be available on the company’s website for approximately 30 days. Freddie Mac’s mission is to make home possible for families across the nation. We promote liquidity, stability, affordability and equity in the housing market throughout all economic cycles....

Continue reading

Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives

Acquire cell therapy manufacturing facility with clinical and commercial capabilities Further ExacTcell platform for additional clinical trials based on successful completion of POC Highlight full year financial results and clarify key financial itemsWARREN, N.J., May 01, 2024 (GLOBE NEWSWIRE) — Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, announced financial results for full year 2023, business highlights, and upcoming operational objectives. “Saving lives remains our duty, and to that end, we remain committed to furthering our ExacTcell™ technology platform by moving Tevogen’s allogeneic cytotoxic CD8+ T lymphocytes (CTLs) into the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.